Dipeptidyl peptidase-4
DPP4proteinDPP-4 regulates GLP-1 stability and directly modulates platelet aggregation and endothelial function in MI.
Pathway placement
Cascade stepPlatelet adhesion & activation
Confidencemedium
RationaleGLP-1 regulator; modulates endothelial function and platelet aggregation.
Also acts inEndothelial activation/erosion, Vascular inflammation
Druggability
DruggableYes
Known drugs / candidates21
Small-molecule tractableYes
Antibody tractableYes
EnsemblENSG00000197635
Assay & specimen
Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum or plasma
Collection tube
Serum separator (gold/red-top, SST) · K2/K3-EDTA (lavender-top)
Method / principle
Sandwich immunoassay (ELISA) — research-grade unless a cleared assay exists
Reagent / substrate
Matched anti-target antibody pair (capture + labeled detection)
Platform
ELISA microplate or multiplex (Luminex/MSD)
Turnaround · availability
Send-out / research · Research-grade (no universal clinical assay)
Human genetic evidence
0.492
Open Targets association (myocardial_infarction)
Literature evidence(4)
- Angiogenic content of microparticles in patients with diabetes and coronary artery disease predicts networks of endothelial dysfunction.Cardiovascular diabetology · 2022 · PMID 35109843 · doi
- Native, Intact Glucagon-Like Peptide 1 Is a Natural Suppressor of Thrombus Growth Under Physiological Flow Conditions.Arteriosclerosis, thrombosis, and vascular biology · 2020 · PMID 31893947 · doi
- Glucagon-like peptide-1 receptor signalling reduces microvascular thrombosis, nitro-oxidative stress and platelet activation in endotoxaemic mice.British journal of pharmacology · 2016 · PMID 27435156 · doi
- CARDIOVASCULAR OUTCOME TRIALS OF THE INCRETIN-BASED THERAPIES: WHAT DO WE KNOW SO FAR?Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2016 · PMID 27819769 · doi